Table 1 Detailed characteristics of xenografted MDS patients.
From: Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes
Patient | Age (years) | Sex | WHO 2016 | IPSS-R | Karyotype | Mutations | Blasts in BM (%) | PLT number (×10E9/L) | Prior treatment |
|---|---|---|---|---|---|---|---|---|---|
P01 | 59 | M | MDS-EB-2 | Very high | Complex aberrant | CBL, DNMT3A, EZH2 | 12 | 29 | AZA, PT, RCT |
P02 | 82 | M | MDS-EB-2 | Very high | Complex aberrant | TET2, TP53 | 13 | 7 | AZA, PT, RCT |
P03 | 65 | M | tMDS-EB-1 | Very high | Complex aberrant | BCOR, KRAS | 5 | 15 | AZA, PT, RCT |
P04 | 71 | M | tMDS-MLD | Low | 46,XY,r(6) (p21q26) [14]/46,XY [6] | ASXL1, RUNX1, SRSF2, TET2 | 1 | 24 | RCT |
P05 | 69 | M | MDS-EB-1 | Very high | Complex aberrant | TP53 | 7 | 15 | AZA, PT, RCT |
P06 | 82 | M | MDS-EB-2 | Very high | 47,XY,+8 [4]/46,XY [21] | ASXL1, RUNX1, STAG2, ZRSR2 | 10 | 15 | None |
P07 | 83 | F | MDS-MLD | int | 46,XX | ASXL1, BCOR, CBL, DNMT3A, EZH2, TET2, WT1 | 4 | 24 | G-CSF |
P08 | 80 | M | MDS-U | int | 47,XY,+8 [3]/46,XY [17] | ASXL1, IDH2, SRSF2, STAG2 | 4 | 80 | ESA |
P09 | 77 | M | MDS with isolated del(5q) | Very low | Del5q | ASXL1, ETV6, EZH2 | 1 | 74 | Deferoxamine, Lenalidomide, PT, RCT |
